Creative Planning Boosts Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Creative Planning grew its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 24.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 31,445 shares of the medical equipment provider’s stock after purchasing an additional 6,105 shares during the quarter. Creative Planning’s holdings in Zimmer Biomet were worth $2,868,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of Zimmer Biomet by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 23,052,925 shares of the medical equipment provider’s stock worth $2,609,130,000 after purchasing an additional 166,763 shares in the last quarter. Dodge & Cox boosted its holdings in Zimmer Biomet by 2.3% in the first quarter. Dodge & Cox now owns 19,564,454 shares of the medical equipment provider’s stock worth $2,214,305,000 after acquiring an additional 446,018 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Zimmer Biomet by 1.4% in the second quarter. Geode Capital Management LLC now owns 5,124,776 shares of the medical equipment provider’s stock worth $465,480,000 after acquiring an additional 69,485 shares in the last quarter. Ameriprise Financial Inc. grew its stake in shares of Zimmer Biomet by 236.0% during the first quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider’s stock worth $517,039,000 after acquiring an additional 3,208,596 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in shares of Zimmer Biomet by 251.3% during the first quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider’s stock valued at $235,571,000 after acquiring an additional 1,488,918 shares in the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. Johnson Rice set a $112.00 target price on shares of Zimmer Biomet in a research note on Wednesday, November 5th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $100.00 price target (down previously from $115.00) on shares of Zimmer Biomet in a report on Thursday, November 6th. Canaccord Genuity Group lowered their price objective on shares of Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating for the company in a research note on Monday, November 10th. UBS Group cut their target price on Zimmer Biomet from $96.00 to $88.00 and set a “sell” rating on the stock in a research report on Thursday, November 6th. Finally, Raymond James Financial raised their target price on Zimmer Biomet from $104.00 to $113.00 and gave the stock an “outperform” rating in a research note on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $109.00.

Zimmer Biomet Stock Up 3.4%

ZBH stock opened at $92.12 on Monday. Zimmer Biomet Holdings, Inc. has a one year low of $85.33 and a one year high of $114.44. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.96 and a current ratio of 1.87. The firm’s fifty day moving average is $97.17 and its 200 day moving average is $96.79. The firm has a market cap of $18.26 billion, a PE ratio of 22.41, a P/E/G ratio of 2.29 and a beta of 0.67.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The business had revenue of $2 billion during the quarter, compared to the consensus estimate of $2.01 billion. During the same quarter in the prior year, the firm posted $1.74 earnings per share. The company’s revenue was up 9.6% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th were issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend was Tuesday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 23.76%.

Insider Activity at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,500 shares of the company’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $104.15, for a total transaction of $156,225.00. Following the completion of the transaction, the senior vice president directly owned 6,833 shares of the company’s stock, valued at $711,656.95. This represents a 18.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 1.39% of the stock is owned by company insiders.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.